Eli Lilly Sues Generic Drug Co. Over Gemzar Patents

Law360, New York (October 31, 2006, 12:00 AM EST) -- Pharmaceutical company Eli Lilly & Co. has targeted a generic drug company in a patent infringement suit related to its top-selling cancer treatment Gemzar.

Eli Lilly brought the suit last week against Mayne Pharma, a Paramus, N.J.-based company that markets generic and specialty injectable drug products, in the U.S. District Court for the Southern District of Indiana.

The Indianapolis, Ind.-based drug maker claimed that Mayne violated two of its patents by filing an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration to...
To view the full article, register now.